Dusa Patent Suit Challenges Compounding Of Levulan
This article was originally published in The Pink Sheet Daily
Executive Summary
New England Compounding Center’s compounding of aminolevulinic acid HCl goes beyond the activities permitted under the FD&C Act, Dusa maintains. The company has also told FDA about its concerns.
You may also be interested in...
FDA’s Compounding Oversight: What Price Safety?
As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.
Dusa Settles Compounding Suit
Dusa has reached a settlement with the New England Compounding Center in its patent infringement lawsuit relating to compounded Levulan (aminolevulinic acid), Dusa said April 10
Dusa Settles Compounding Suit
Dusa has reached a settlement with the New England Compounding Center in its patent infringement lawsuit relating to compounded Levulan (aminolevulinic acid), Dusa said April 10